Get Phases from Arsenic Anomalous Scattering: de novo SAD Phasing of Two Protein Structures Crystallized in Cacodylate Buffer by Liu, Xiang et al.
Get Phases from Arsenic Anomalous Scattering: de novo
SAD Phasing of Two Protein Structures Crystallized in
Cacodylate Buffer
Xiang Liu, Heng Zhang, Xiao-Jun Wang, Lan-Fen Li, Xiao-Dong Su*
State Key Laboratory of Protein and Plant Gene Research and Biodynamic Optical Imaging Center (BIOPIC), School of Life Sciences, Peking University, Beijing, China
Abstract
The crystal structures of two proteins, a putative pyrazinamidase/nicotinamidase from the dental pathogen Streptococcus
mutans (SmPncA) and the human caspase-6 (Casp6), were solved by de novo arsenic single-wavelength anomalous
diffraction (As-SAD) phasing method. Arsenic (As), an uncommonly used element in SAD phasing, was covalently
introduced into proteins by cacodylic acid, the buffering agent in the crystallization reservoirs. In SmPncA, the only cysteine
was bound to dimethylarsinoyl, which is a pentavalent arsenic group (As (V)). This arsenic atom and a protein-bound zinc
atom both generated anomalous signals. The predominant contribution, however, was from the As anomalous signals,
which were sufficient to phase the SmPncA structure alone. In Casp6, four cysteines were found to bind cacodyl, a trivalent
arsenic group (As (III)), in the presence of the reducing agent, dithiothreitol (DTT), and arsenic atoms were the only
anomalous scatterers for SAD phasing. Analyses and discussion of these two As-SAD phasing examples and comparison of
As with other traditional heavy atoms that generate anomalous signals, together with a few arsenic-based de novo phasing
cases reported previously strongly suggest that As is an ideal anomalous scatterer for SAD phasing in protein
crystallography.
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Introduction
SAD (single-wavelength anomalous diffraction) is a widely used
phasing method in protein crystallography due to its advantages
such as single dataset collection, minor radiation damage, and no
need for maximum anomalous effects etc. [1]. In the recent years,
synchrotron radiation (SR) X-ray sources have been established all
over the world [2]. Given SR’s advantageous features such as
extremely high intensity and stability and tunable wavelength
selection, SR facilities have become the most favorable choices for
diffraction data collection for protein crystallography. The
statistics from PDB (protein data bank) database shows that nearly
80% of protein crystallographic diffraction data were collected on
SR facilities so far (http://biosync.sbkb.org/index.jsp, until 2010).
On the other hand, new software packages for data processing,
phasing, density modification and model auto-building increase
the efficiency and throughput in SAD phasing [3]. These technical
progresses have made the SAD method the most convenient and
powerful phasing method in protein crystallography.
The anomalous scatterers in SAD phasing method can be atoms
inherited in native proteins (e.g. Zn, Fe, Cu in metalloproteins [1]
or S from cysteines and methionines [4,5]); or artificially
introduced into proteins by soaking (i.e. heavy atoms such as
Hg, Au, Pt, halide salts [6,7] and lanthanide [8,9]); or genetically
incorporated (Selenomethionine (Se-Met) substitution [10] and
lanthanide binding tags (LTB-tags) fusion for proteins [11]); or
chemically synthesized (bromouracyl/bromocytosin substitution
for nucleic acids [12,13]). Heavy-atom or halide soaking method
requires extra efforts for the screenings of soaked compounds, and
the experimental conditions can only be obtained by trial and
error. Moreover, soaking procedures may bring in considerable
disturbances to the protein structure and the crystal lattice,
resulting in the decrease of the diffraction resolution. By contrast,
the Se-Met substitution method has been more extensively used
due to its definite incorporation protocol and high success rate
[14]. The first Se-Met labeled protein structure was reported in
1990 [10]. Till August 2010, more than 5000 Se-Met labeled
crystal structures have been deposited in the PDB database
(http://www.pdb.org/pdb/home/home.do, August 2010, PDB
statistics,). Increasing number of newly-built synchrotron beam-
lines set their optimal wavelengths around the selenium K
absorption edge (,0.98 A ˚) [15] and nearly half of the structures
solved by SAD phasing method took selenium as the anomalous
scatterer [14].
Arsenic (As) is located beside selenium in the periodic table with
a K absorption edge (,1.04 A ˚) close to that of Se (,0.98 A ˚). This
feature suggests that users can collect As anomalous signals on an
Se-dedicated SR beamline (Fig. 1). Till now, more than 200
structures with arsenic atoms presented in their coordinates in the
PDB database can be found, but only three protein structures have
been reported to use As as the anomalous scatterers for phasing
[15,16,17]. The reasons that As have been neglected for long as a
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its toxicity [19,20] and a lack of general protocols for As
incorporation. In fact, arsenic compound is toxic because it can
interact with thiol-groups in biological macromolecules. Making
use of this reaction [21], however, we can covalently introduce As
into protein samples.
In this paper, we have made in depth analyses to evaluate the
incorporation of arsenic atom into proteins and the general
application of As as a common anomalous scatterer. We present
twocasesofproteinstructuresdetermined byAs-SADphasinginour
laboratory during the last two years, a putative PncA from
Streptococcus mutans and caspase-6 from Homo sapiens. The crystalliza-
tion conditions of both proteins contained cacodylate buffer, which
specifically modified surface cysteines of the proteins. Both datasets
were collected on SR facilities at the wavelength of 1.000 A ˚,t h e
high-energy end from the K absorption edge of As (, 1.04 A ˚), and
sufficient anomalous signals for SAD phasing were obtained. Our
current studies demonstrated that cacodylate buffer is an effective
reagent to covalently modify protein surface cysteines, and that As
could serve as an ideal anomalous scatterer in SAD phasing method.
Materials and Methods
SmPncA
Protein preparation. SmPncA gene was cloned into the
pET28a expression vector with an N-terminal (His)6-tag, and over-
expressed in Escherichia coli BL21(DE3) strain at 30uC for 8 hours.
The SmPncA proteins were purified in two steps with a nickel
chelating column first (5 ml HiTrap HP column, GE Healthcare/
Amersham), followed by a gel filtration column (120 ml Superdex-
75, GE Healthcare/Amersham). The supernatant of cell lysate was
loaded on a nickel column equilibrated in buffer containing
20 mM Tris-HCl pH 7.5, 500 mM NaCl. The loaded column was
then washed with equilibration buffer containing 100 mM
imidazole, and the target proteins were eluted with a linear
gradient with the equilibration buffer containing 500 mM
imidazole. The proteins were further purified by gel filtration in
buffer containing 20 mM Tris-HCl pH 7.5 and 200 mM NaCl.
Purified proteins were concentrated for crystallization using the
Amicon Ultra Centrifugal Filter Devices of 10,000 MWCO
(Millipore Corporation). The concentration of the purified
SmPncA was about 20 mg/ml.
Crystallization and data collection. Crystals of SmPncA
were grown in 20% v/v 2-methyl-2,4-pentanediol (MPD), 0.1 M
sodium cacodylate pH 4.5, and crystals suitable for data collection
were obtained in half a month. Diffraction data were collected on
the Beamline BL5A at the Photon Factory, Tsukuba, Japan. The
crystal was flash frozen in liquid nitrogen and then maintained on
the goniometer at 100 K in a stream of cold nitrogen. The
diffraction data were collected from one single crystal at
wavelength of 1.000 A ˚, and 360 frames were collected with 1u
oscillation per image. The data were indexed, integrated and
scaled by the program XDS [22,23]. The statistics of the data are
summarized in Table 1.
SAD phasing and refinement of SmPncA. Data quality of
SmPncA was checked by the program Xtriage [24] of PHENIX
software package. The crystal belongs to the space group P212121
with cell dimensions of a=76.49 A ˚, b=80.12 A ˚, c=130.96 A ˚.
SmPncA contains 183 amino acid residues with a molecular weight
of 20.5 kDa. There are four molecules per asymmetric unit (ASU)
with a Matthews coefficient of 2.45 and solvent content of 49.8%.
The locations of the heavy atom sites were determined by the
program SHELXD [25]. The phenix.autosol in the PHENIX software
package [26] was used to refine the locations of substructures,
calculate the initial phases, and make Density Modification (DM),
Non-Crystal Symmetry (NCS) improvement and model auto-
building. After the initial model auto-building, 661 of total 728
residues were successfully built and 610 residues were correctly
placed. The final model was manually completed by the program
Coot [27] and further refined by phenix.refine in the PHENIX
software package. The graphics program PyMOL [28] was used in
the structural analysis and production of the figures. Anomalous
difference Fourier map calculated with phases from the final
model showed two obvious peaks in one monomer above 5 s
(Fig. 2A). Electron density is show around Cys136 in smPncA
(Fig. 3A, 3C, 3E, 3G). The coordinates and structure factors of
SmPncA have been deposited in the Protein Data Bank with the
PDB ID code 3S2S.
Caspase-6
Protein preparation, crystallization, data collection and
structure information. Wild type human Casp6 were
prepared as previously published [27]. Briefly, the Casp6
construct was cloned into the pET21b expression vector with a
Figure 1. The plot of theoretical f prime and f double prime for arsenic and selenium. In this plot, the lines of arsenic are in green while
the lines of selenium are in blue. The plot is generated from the following website: http://skuld.bmsc.washington.edu/scatter/.
doi:10.1371/journal.pone.0024227.g001
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strain at 18uC for 20 hours. Proteins for crystallization were
purified in two steps, nickel chelating column and gel filtration
chromatography, and 10mM DTT was added to the purified
proteins. In order to obtain completely activated Casp6, 1 ng/
mLa c t i v eC a s p 3w a sa d d e di n t o5mg/mL purified Casp6 at
4uC overnight. The Casp6 crystals were grown by the sitting
drop vapor diffusion method with an inhibitor Ac-VEID-CHO
added. Crystals were obtained in 20% w/v PEG 8000, 0.2 M
magnesium acetate, and 0.1 M sodium cacodylate pH 6.5 at
20uC.
Diffraction data were collected on the Beamline BL6A at the
Photon Factory, Tsukuba, Japan. The crystal was flash frozen in
liquid nitrogen and then maintained on the goniometer at 100 K
in a stream of cold nitrogen. The data were collected from one
single crystal at wavelength 1.000 A ˚, and 180 frames were
collected with 1u oscillation per image. The data were indexed,
integrated by the program Mosflm [29] and scaled by program
Scala [30] of the CCP4 software package [31]. The statistics of these
data are also summarized in Table 1.
SAD phasing for Casp6. The crystal structure of human
Casp6 was first determined by Molecular Replacement method
[32]. The molecular weight of Casp6 monomer is about 32 kDa
and there is a homodimer in the ASU. In the structure, several
cysteines on the surface were found covalently bound to
cacodyl, a reductive product of cacodylate in the presence of
DTT [18,21] (Fig. 2B). We then made an attempt to make use
of the As anomalous signals to determine the structure de novo.
The data of Casp6 were re-scaled as SAD data by the Program
Scala. The raw Bijvoet differences contributed by cacodyl were
calculated to be 1.9% by the Hendrickson formulation [33].
The SAD phasing procedure of Casp6 was identical to that of
SmPncA. After the initial model building, about 167 residues
were built into the electron density and the overall figure of
merit (FOM) was 27%. Some obvious secondary structural
fragments could be observed in the phase improved map. The
initial model was then input into the program phenix.autobuild
[26], another seven rounds of model auto-building were
executed, after which 466 residues were auto-built. In this
case, the As-SAD phasing could be used to solve the structure
of Casp6 independently without any information from other
models. Anomalous difference Fourier map calculated with
phases from the final model showed eight obvious peaks in one
ASU above 5 s (Fig. 2B). Electron density is shown around
Cys264 in casp6 (Fig. 3B, 3D, 3F, 3H). The coordinates and
s t r u c t u r ef a c t o r so fc a s p 6h a v eb e e nd e p o s i t e di nt h eP r o t e i n
Data Bank with the PDB ID code 3S70.
Figure 2. Anomalous difference Fourier map calculated with final phases at 5 s. A. Atoms are shown as sticks model, and colored as
follows: carbon, green; oxygen, red; nitrogen, blue; zinc, grey; arsenic, purple. B. The Casp6 structure is shown as a backbone representation. The
cysteines modified by cacodylic acid are presented in the model.
doi:10.1371/journal.pone.0024227.g002
Table 1. Data collection and Statistics from crystallographic
analyses.
SmPncA Ac-VEID-CHO inhibited Casp6
Wavelength (A ˚) 1.000 1.000
Space group P 212121 P 21
Cell dimension
a, b, c (A ˚) 76.5, 80.1, 130.9 55.4, 89.5, 61.1
b=111.70
Resolution (A ˚) 50.0–1.6 (1.7–1.6) 25.30–1.63 (1.71–1.63)
Rsym
a (%) 5.6(68.2) 8.3(32.9)
Mean I/sI 26.9(4.4) 7.0 (2.2)





Anomalous redundancy 7.1 1.3
Refinement
Resolution range (A ˚) 20.0–1.7 20.00–1.63
Number of reflections 88570 68845
Rwork
b/Rfree
bc (%) 16.03/ 19.12 16.30/ 19.37
Average B-factors 22.52 10.53
No of protein residues 727 480
No of waters 598 681
No of ligands 8 11
rms. deviation
d
Bond lengths (A ˚) 0.009 0.007
Bond angles (u) 1.164 1.098
Values in parentheses are for the highest resolution shell.
aRsym =g|Iobs_Iavg|/gIobs.
bRwork, free =g||Fobs|_|Fcalc|| / g|Fobs|.
cRfree values are calculated for a randomly selected 5% of the data that was
excluded from the refinement.
dRoot mean square deviation from ideal/target geometries.
doi:10.1371/journal.pone.0024227.t001
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PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e24227Figure 3. Electron density is shown around Cys136 in smPncA (A,C,E,G) and Cys264 in Casp6 (B,D,F,H). A, B: SAD phases from phaser
prior to any refinement steps. C, D: SAD phases form resolve after DM and NCS averaging. E, F: 2Fo-Fc map with the final phase from phenix.refine and
G, H: Fo-Fc omit density map. This figure was generated by PyMol. Atoms are shown as stick and colored as follows: carbon, green; oxygen, red;
nitrogen, blue; zinc, grey; arsenic, purple. The electron density is contoured at 1.5 s, except that in the omit map (G, H), the positive density (Green)
was contoured at 4 s.
doi:10.1371/journal.pone.0024227.g003
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Site Occupancy from Phaser Occupancy in the final model B-factor in the final model Atom
1 0.81 0.80 23.79 As in chain B
2 0.74 0.80 25.02 As in chain A
3 0.81 0.80 23.72 As in chain C
4 0.78 0.80 24.59 As in chain D
5 0.45 0.80 25.46 Zn in chain B
6 0.41 0.80 28.05 Zn in chain D
7 0.40 0.60 25.10 Zn in chain C
8 0.37 0.80 29.15 Zn in chain A
doi:10.1371/journal.pone.0024227.t002
Figure 4. Anomalous differences between arsenic and zinc. A. The anomalous signal reduction as a function of resolution. The peak heights of
the heavy atoms were derived from the anomalous Fourier map, which was calculated using final phases. B. SAD phase errors (after density
modification) against the final model as a function of resolution cutoff. Different colors represent the phases calculated from different anomalous
scatterers: phases calculated from zinc atoms are shown in silver, those from arsenic atoms are shown in purple and from both are shown in orange.
doi:10.1371/journal.pone.0024227.g004
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Arsenic/zinc SAD phasing of SmPncA
SmPncA consists of 183 residues with only one cysteine, Cys136,
serving as the potential target for cacodylate modification. During
the SAD phasing, eight heavy atom sites were found by SHELXD
and confirmed by the program Phaser [34] in Phenix.autosol, and all
of them were taken as arsenic atoms for phase calculation.
However, according to the Matthews coefficient, there are only
four molecules per ASU, indicating that there should be only four
sites for the substructures. Since there was a classical zinc-finger
fold structure found in the final model, we identified the other four
anomalous scatterers as zinc atoms and further confirmed the
existence of zinc atoms in the protein by Inductively Coupled
Plasma Atomic Emission Spectrometry ICP-AES (data not
shown). An anomalous difference Fourier map calculated with
phases from the final model showed two obvious peaks in one
monomer above 5 s (Fig. 2A).
As the substructures solution shown in Table 2, there is a visible
gap of occupancies between the two types of anomalous scatterer
atoms. The occupancy of As is about 80%, whereas that of Zn is
only 40%. The difference of the anomalous peak heights is
consistent with the ranking in the output of program Phaser
(Fig. 4A). All the arsenic atoms share similar anomalous peak
heights, so do the zinc atoms. However, the peak heights of As are
almost twice as those of Zn in the resolution range shown,
indicating the phasing power of As was dominating during
structure determination.
To test the independent phasing power of As and Zn in
SmPncA, the two types of heavy atoms were input into the same
program pipeline separately. Program Solve [35] in phenix.autosol
was used to calculate the initial phases. Further data improvement
and model-building were carried out by the phenix.autosol pipeline.
The improved phases before model-building were compared with
the phases calculated from the final model, and phase errors were
estimated (Fig. 4B). The model generated by As-SAD phasing
consisted of 558 residues, and the remaining residues could be
easily identified and placed as well. By contrast, zinc atom alone
could not provide enough anomalous phasing power to generate a
reasonable density map for further model building. Besides, the
phase error plot clearly shows that the arsenic scatterers made the
major contribution to SAD phasing in this case (Fig. 4B).
Arsenic Modification of Cysteine in SmPncA and Casp6
Most of experienced protein crystallographers often encounter
unexpected anomalous scatterers during structure determinations,
and these adventitious anomalous scatterers may be unverified
metal ions, additive ions or molecules from the crystallization
conditions. Arsenic atom sometime presents one of these kinds of
anomalous scatterers. In both SmPncA and Casp6, arsenic atoms
were incorporated into proteins by chemical reaction between
cysteines and cacodylic acid. Cacodylic acid is an As (V)
compound, widely used as buffering agent in protein purification
and crystallization screenings. It has a pKa of 6.3, and its most
effective buffering range is between 5.0 and 7.5. During
crystallization, cacodylic acid can specifically modify the cysteine
residues on protein surface and form a covalent bond between As
and cysteine sulfur.
In the case of Casp6, proteins were prepared with DTT to
avoid the formation of disulfide bond between free cysteines.
When protein solution containing DTT was mixed with the
crystallization reservoir, cacodylic acid was spontaneously
reduced to a chemically more active As (III)-thiolate intermedi-
ate. The As (III) reagent in turn reacted with cysteines by a thiol
exchange process, resulting in the formation of a cacodyl-cysteine
product [18]. In this case, four out of ten cysteines in the protein
covalently bound to As, while the other six cysteines were either
solvent inaccessible or occupied by the inhibitor Ac-VEID-CHO
in the active site.
Figure 5. A cysteine in the SmPncA is shown covalently bound
to cacodylate without adding reducing agents.
doi:10.1371/journal.pone.0024227.g005
Figure 6. A putative three-stage cysteine modification mechanism for SmPncA. In stage 1, proton abstraction by Asp9 would increase the
nucleophilicities of Cys136 and facilitate nucleophilic attack at cacodylic acid (CAD); Proton donation from Asp9 to the hydroxyl group of the CAD
would promote As-O bond cleavage and release of H2O as the intermediate in stage 2 collapses to give a dimethylarsinoyl fixed Cys136 in stage 3.
doi:10.1371/journal.pone.0024227.g006
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the protein preparation or crystallization. Cysteines were in
contact with dimethylarsinoyl, an As (V) group. Organic As (V)
reagents usually do not react effectively with organic thiols.
However, surrounding residues, such as aspartate or histidine, can
catalyze the thiol exchange reaction between As (V) and cysteines
(Fig. 5). Similar phenomena were also found in other examples
such as AbPncA [36], a putative nitrilase superfamily protein [37]
and a pteridine reductase [38]. Here we propose a plausible three-
stage cysteine modification mechanism for SmPncA without DTT
(see Fig. 6), involving the Cys136 as a nucleophile to attack at
arsenic in the cacodylate, and Asp9 as general acid to donate a
proton.
Comparison of arsenic with traditional phasing methods
The covalent binding of As to cysteine makes As easier to reach
high occupancy in proteins compared with those non-covalent
binding metals. In SmPncA, the stark difference in anomalous
contributions between As and Zn in phasing power is mainly due
to the difference in heavy-atom incorporation manners, although
the f’’ of As and Zn are slightly different (at 1.000 A ˚ wavelength, f’’
(As) is 3.7e and f’’ (Zn) is 2.7e). Compared with the coordination
bonds between Zn and surrounding residues, the covalent bond
between arsenic and cysteine is more stable and tend to generate
high-occupancy site in the substructure determination. Therefore,
it is more effective to use covalently bound As as anomalous
scatterers than traditional soaked heavy atoms or metal scatterers
in metalloproteins.
Some previous studies also showed that As modification could
be an important complementary method to Se-Met substitution
method in SAD phasing. In the case of SPR14 protein [16], only
the combined anomalous signals from both Se-Met and As were
able to produce initial phases for structural determination. In some
cases, As-SAD phasing is more advantageous than Se-SAD
phasing, such as the structure determinations of HIV-1 integrase
[17,21]. Se-Met substitution method is quite expensive and time-
consuming, usually gives lower protein expression level, and not
always works well for recombinant proteins in eukaryotic
expression systems. By contrast, the reaction between cacodylate
and free cysteines on protein surface can be easily handled without
extra steps during protein expression and purification.
In the case of SmPncA, one As anomalous scatterer could phase
up to 200 amino acid residues. According to statistical analyses,
the occurrence of cysteines in proteins is about 2% [39,40,41],
therefore, if one out of four cysteines could be solvent-accessible
and modified by As, many proteins would have fairly good
chances to be successfully phased by As-SAD. In addition to the
potential phasing capacity, surface-cysteine modification by
arsenic compound could be beneficial to protein crystallization
as well [42,43]. Modified surface cysteines are not able to form
unfavorable disulfide bonds, and the small arsenic compound will
not bring in significant disturbance to protein structures.
The reaction of cacodylic acid with cysteine has been observed
many times before. According to the statistical data, more than
eighty protein structures in the PDB database have As-modified
cysteines. However, this reaction has not been notified to serve as
an effective and general method to introduce As into proteins.
Based on our studies, we propose that the cacodylate buffer can be
used to crystallize proteins that have free surface cysteines.
In conclusion, we have solved the crystal structures of two
proteins by As-SAD phasing method and further studied the
details of arsenic incorporation by the reaction between cysteine
and cacodylate, the buffering agent in the crystallization
conditions. We would like to suggest to the protein crystallography
community that cacodylate buffer can be used to introduce arsenic
simply into proteins for SAD phasing in general.
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